Fatty Liver Disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
In patients with nonalcoholic steatohepatitis (NASH), PNPLA3 GG compared to CC was associated with higher AST levels [38.4±25.3 versus 36.7±40.1IU/L, p=0.0395)] and with the presence of liver fibrosis (≥F2 fibrosis, p=0.0272).
|
31054980 |
2020 |
Fatty Liver Disease
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
This study provides the first evidence that a Pnpla3 ASO therapy can improve all features of NAFLD, including liver fibrosis, and suppress the expression of a strong innate genetic risk factor, Pnpla3 148M, which may open up a precision medicine approach in NASH.
|
30772256 |
2019 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
In patients without, but not in those with NASH, significant fibrosis was associated with steatosis grade and the PNPLA3 I148M variant.
|
30708111 |
2019 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A sequence variation in patatin like phospholipase domain-containing protein 3 (PNPLA3), rs 738409, is strongly associated with the progression of fatty liver disease.
|
31062641 |
2019 |
Fatty Liver Disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
Expression of a ubiquitylation-resistant form of PNPLA3 in mice caused accumulation of PNPLA3 on hepatic LDs and development of FLD.
|
31019090 |
2019 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
A variant (148M) in patatin-like phospholipase domain-containing protein 3 (PNPLA3) is a major risk factor for fatty liver disease.
|
30802989 |
2019 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Second, although the strongest genetic risk alleles for NAFLD (ie, the 148Met allele in PNPLA3 and the 167Lys allele in TM6SF2) are associated with increased liver fat content and progression to NASH and cirrhosis, these alleles are also unexpectedly associated with an apparent protection from cardiovascular disease.
|
30174213 |
2019 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Logistic regression was used to test associations [OR (95% CIs)] between low BMD, and both NASH and PNPLA3 I148M genotypes.
|
30176114 |
2018 |
Fatty Liver Disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
PNPLA3 and TM6SF2 determine the risk of NASH and significant fibrosis, even after adjustment for insulin resistance, and exert an additive effect on NASH and significant fibrosis.
|
29193269 |
2018 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Because SA-ki and IM-ki both cause FLD and yet have opposite effects on the lipidomic profile of LDs, we conclude that the FLD associated with genetic variation in PNPLA3 is not related to the enzyme's role in remodeling LD lipids.
|
29555681 |
2018 |
Fatty Liver Disease
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
PNPLA3 expression in Hispanics could be decisive in NAFLD pathogenesis, it's highly prevalent and it's a key to condition and determine the spectrum associated, SS, NASH and fibrosis.
|
29055919 |
2018 |
Fatty Liver Disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
Silibinin can ameliorate some metabolic alterations and induce some molecular changes by activating the CFLAR-JNK pathway and thereby regulating its downstream target genes involved in lipid metabolism (PPARα, SREBP-1C and PNPLA3), glucose uptake (PI3K-AKT), oxidative stress (NRF2, CYP2E1, CYP4A) and inflammatory response(NO) in OA-treated HepG2 cells demonstrating its possible use in ameliorating various symptoms of NASH.
|
30248539 |
2018 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3-G/G-genotype seems to double the risks of hepatic decompensation and (liver-related) mortality in patients with portal hypertension due to fatty liver disease.
|
29956823 |
2018 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation.
|
28520213 |
2017 |
Fatty Liver Disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α.
|
28264426 |
2017 |
Fatty Liver Disease
|
0.200 |
Biomarker
|
disease |
BEFREE |
Presence of minor allele (G) of PNPLA3 was also associated with moderate/severe steatosis (≥33%) both in patients with (OR: 2.405 [CI95%: 1.220-4.744], P=0.011) and without MetS (OR: 2.481 [CI95%: 1.172-5.250], P=0.018), but was only associated with NASH (OR: 2.002 [CI95%: 1.062-3.772], P=0.032) and liver fibrosis (OR: 2.646 [CI95%: 1.299-5.389], P=0.007) in patients without MetS.
|
27908400 |
2017 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The genetic polymorphism I148M of the patatin-like phospholipase domain-containing 3 (PNPLA3) is associated with hepatic steatosis and its progression to steatohepatitis (NASH), fibrosis and cancer.
|
29116096 |
2017 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We screened the entire coding region of the PNPLA3 gene in DNA samples of 393 obese liver biopsy patients with varying degrees of fatty liver disease.
|
27288299 |
2016 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 rs738409 polymorphism is associated with fatty liver disease, alcoholic or non-alcoholic (NAFLD) and hepatocellular carcinoma (HCC).
|
26493626 |
2016 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
The PNPLA3 rs738409 GG genotype increases susceptibility of NASH in severely obese Asians with NAFLD and correlates to histologic severity of NAFLD.
|
25240529 |
2016 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
We genotyped 51 single-nucleotide polymorphisms (SNPs) previously reported as T2DM or NASH susceptibility loci (PNPLA3) compared between the DM-HCC and DM-non-HCC groups with regard to allele frequencies at each SNP.
|
26337813 |
2016 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Further, there was an additive effect of the PPARGC1A rs8192678 GA/AA genotype and the PNPLA3 rs738409 GG genotype on the presence of NASH (OR 6.83; 95% CI 1.61-29.01; P = 0.009).The PPARGC1A rs8192678 GA/AA genotype and the PNPLA3 rs738409 GG genotype had an additive effect on NASH in severely obese Taiwanese patients.
|
27015186 |
2016 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
PNPLA3 genotypes partly affected the definition of NASH by the NAFLD activity score, but TM6SF2 genotypes did not affect the definition of NASH.
|
26610348 |
2016 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
These findings suggest that the rs738409 polymorphism in PNPLA3 gene confers high cross-ethnicity risk for NAFLD and NASH development.
|
25791171 |
2015 |
Fatty Liver Disease
|
0.200 |
GeneticVariation
|
disease |
BEFREE |
Four linked SNPs of PNPLA3 (rs738409, rs3747206, rs4823173, and rs2072906) are correlated with susceptibility to NAFLD, NASH, liver fibrosis, and HBV dynamics in CHB patients.
|
26229402 |
2015 |